6-K filed Aug 17, 2026 at 06:19 ET
HUTCHMED announced positive Phase III SAFFRON trial results showing ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) achieved statistically significant and clinically meaningful improvements in both progression-free survival (PFS) and overall survival (OS) versus chemotherapy in MET-driven EGFR-mutated NSCLC patients who progressed on TAGRISSO. This is the first global Phase III trial to demonstrate both PFS and OS benefits in this setting, providing pivotal data to support global regulatory filings for the combination. The results de-risk the global registration pathway for ORPATHYS, a key pipeline asset co-developed with AstraZeneca, and address a significant unmet need in a large patient population.